Luciano Costa, MD, PhD, discusses the considerations for managing infection risk with bispecific antibodies in multiple myeloma.
Luciano Costa, MD, PhD
Luciano Costa, MD, PhD, is Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham
Articles by Luciano Costa, MD, PhD
FDA clears teclistamab plus daratumumab for early-relapse multiple myeloma, delivering striking PFS gains and scalable outpatient use.
Luciano Costa, MD, PhD, discussed why the lack of high-grade cytokine release syndrome in the MajesTEC-3 trial should encourage the use of teclistamab.
Luciano Costa, MD, PhD, discusses the how the MajesTEC-3 trial's 83% improvement in PFS contributed to a 3-month turnaround to FDA approval.